About: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia
Creator	Garcia, J Gluckman, E Michel, G Renaud, M Rocha, V Rodrigues, C Labopin, M Mohty, M Willemze, R Rio, B Socié, G Beguin, Y Boudjedir, K Devos, T Ferra, C Garnier, F Herr, A-L Ionescu, I Kö Gler 16, G Lecchi, L Loiseau, P Madero, L Navarrete, C Sanz, G Sirvent, A
Source	PMC
abstract	Donor killer cell immunoglobulin-like receptor (KIR)-ligand incompatibility is associated with decreased relapse incidence (RI) and improved leukemia-free survival (LFS) after haploidentical and HLA-mismatched unrelated hematopoietic stem cell transplantation. We assessed outcomes of 218 patients with acute myeloid leukemia (AML n=94) or acute lymphoblastic leukemia (n=124) in complete remission (CR) who had received a single-unit unrelated cord blood transplant (UCBT) from a KIR-ligand-compatible or -incompatible donor. Grafts were HLA-A, -B or -DRB1 matched (n=21) or mismatched (n=197). Patients and donors were categorized according to their degree of KIR-ligand compatibility in the graft-versus-host direction by determining whether or not they expressed HLA-C group 1 or 2, HLA-Bw4 or HLA-A3/-A11. Both HLA-C/-B KIR-ligand- and HLA-A-A3/-A11 KIR-ligand-incompatible UCBT showed a trend to improved LFS (P=0.09 and P=0.13, respectively). Sixty-nine donor–patient pairs were HLA-A, -B or -C KIR-ligand incompatible and 149 compatible. KIR-ligand-incompatible UCBT showed improved LFS (hazards ratio=2.05, P=0.0016) and overall survival (OS) (hazards ratio=2.0, P=0.004) and decreased RI (hazards ratio=0.53, P=0.05). These results were more evident for AML transplant recipients (2-year LFS and RI with or without KIR-ligand incompatibility 73 versus 38% (P=0.012), and 5 versus 36% (P=0.005), respectively). UCBT for acute leukemia in CR from KIR-ligand-incompatible donors is associated with decreased RI and improved LFS and OS. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/leu.2008.365) contains supplementary material, which is available to authorized users.
has issue date	2009-01-08(xsd:dateTime)
bibo:doi	10.1038/leu.2008.365
bibo:pmid	19151783
has license	no-cc
sha1sum (hex)	585cc7e6d3b2fb27eca260a8c223ecacee28d0c5
schema:url	https://doi.org/10.1038/leu.2008.365
resource representing a document's title	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia
has PubMed Central identifier	PMC7101531
has PubMed identifier	19151783
schema:publication	Leukemia
resource representing a document's body	covid:585cc7e6d3b2fb27eca260a8c223ecacee28d0c5#body_text
is schema:about of	named entity 'acute myeloid leukemia' named entity 'ratio' named entity 'Grafts' named entity 'AML' named entity '149' named entity 'LEUKEMIA' named entity 'HLA-C' named entity 'UNRELATED' named entity 'COMPATIBLE' named entity 'ACUTE MYELOID LEUKEMIA' named entity '0.012' named entity 'HOST' named entity 'SINGLE' named entity 'A11' named entity '004' named entity 'HLA' named entity '282' named entity 'ACUTE LEUKEMIA' named entity 'TRANSPLANT' named entity 'IMPROVED' named entity 'HAPLOIDENTICAL' named entity 'INCIDENCE' named entity '1 OR 2' named entity '28P' named entity 'RATIO' named entity 'EXPRESSED' named entity 'RESULTS' named entity 'GRAFT' named entity 'CORD BLOOD' named entity '0.05' named entity 'LFS' named entity 'survival' named entity 'DRB1' named entity 'LFS' named entity 'group 1' named entity 'ligand' named entity 'cord blood' named entity 'KIR' named entity 'ligand' named entity 'HLA-A3' named entity 'KIR' named entity 'HLA-A' named entity 'HLA' named entity 'KIR' named entity 'KIR' named entity 'acute leukemia' named entity 'receptor' named entity '21 days' named entity 'Clinical studies' named entity 'acute lymphoblastic leukemia' named entity 'univariate analysis' named entity 'KIR3DL2' named entity 'ligand' named entity 'NK-cell' named entity 'acute lymphoblastic leukemia' named entity 'ligand' named entity 'ligand'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software